CCL2 and neoplasm: Moreover, mRNA‐based anti‐tumor vaccines can help generate an immune‐friendly tumor microenvironment (TME) through activating toll‐like receptors (TLRs) and retinoic acid‐inducible gene I (RIG‐I) and secreting type I interferon, as well as chemokine GRO, MCP‐1, RANTES, and MDC.75, 76